Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

Basit Öğe Kaydı
dc.authorid0000-0002-1407-2334
dc.authorid0000-0001-8489-7449
dc.contributor.authorMouttet, Brice
dc.contributor.authorVinti, Luciana
dc.contributor.authorAncliff, Philip
dc.contributor.authorBodmer, Nicole
dc.contributor.authorBrethon, Benoit
dc.contributor.authorCario, Gunnar
dc.contributor.authorChen-Santel, Christiane
dc.contributor.authorElitzur, Sarah
dc.contributor.authorHazar, Volkan
dc.contributor.authorKunz, Joachim
dc.contributor.authorMoericke, Anja
dc.contributor.authorStein, Jerry
dc.contributor.authorVora, Ajay
dc.contributor.authorYaman, Yöntem
dc.contributor.authorSchrappe, Martin
dc.contributor.authorAnak, Sema
dc.contributor.authorBaruchel, Andre
dc.contributor.authorLocatelli, Franco
dc.contributor.authorvon Stackelberg, Arend
dc.contributor.authorStanulla, Martin
dc.contributor.authorBourquin, Jean-Pierre
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:49:33Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:49:33Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000469839300005
dc.descriptionPubMed ID: 30765470
dc.description.abstractTCF3-HLF-positive leukemia represents a rare subtypeof childhood acute lymphoblastic leukemia (ALL), characterized by a high rate of treatment failure despite treatment intensification and allogeneic stem cell transplantation (SCT). Given the high and homogeneous expressionof CD19 on blast cells of this leukemia subtype, thesepatients may benefit from CD19-directed immunotherapy. Here, we report the experience on nineTCF3-HLF-positive ALL patients, most of whom weretreated early in first consolidation with blinatumomab asa bridge to SCT between 2015 and 2018. Treatment withblinatumomab was generally well tolerated; reversibleneurotoxicity was observed in two patients. All ninepatients achieved molecular remission after blinatumomab treatment; seven underwent SCT and for onepatient SCT is planned. Median follow up after start ofblinatumomab treatment was 342 days, and four patientsremain in molecular remission after a follow up of 1317,1292, 1245, and 342 days, respectively. Three patientsdied because of infectious complications not directlyrelated to blinatumomab, because they occurred eitherafter SCT or after emergence of a CD19-negativeleukemia clone. In the light of these encouraging observations, CD19-directed immunotherapy should be considered early after induction chemotherapy inTCF3-HLF-positive ALL children and patients’ outcomemonitored systematically by study groups.
dc.identifier.citationMouttet, B., Vinti, L., Ancliff, P., Bodmer, N., Brethon, B., Cario, G. ... Bourquin, J.P. (2019). Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 104(6), E244-E247. https://dx.doi.org/10.3324/haematol.2018.210104
dc.identifier.doi10.3324/haematol.2018.210104
dc.identifier.endpageE247
dc.identifier.issn0390-6078
dc.identifier.issue6
dc.identifier.scopusqualityQ1
dc.identifier.startpageE244
dc.identifier.urihttps://dx.doi.org/10.3324/haematol.2018.210104
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1647
dc.identifier.volume104
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFerrata Storti Foundaition
dc.relation.ispartofHaematologicaen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDebris
dc.subjectEDDY
dc.subjectMandibular Molar
dc.subjectRoot Canal Preparation
dc.subjectSmear Layer
dc.titleDurable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
dc.typeLetter

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Hazar, Volkan-2019.pdf
Boyut:
476.38 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu